Latest filing published 03 Mar 2021 for Adaptimmune Therapeutics PLC, €232k.
Filing timeline
BuySaleInsider track record
Helen Katrina Tayton-Martin: trading record in brief
Helen Katrina Tayton-Martin discloses dealings in Adaptimmune Therapeutics PLC to SEC (Form 4). In total, 4 filings cover trades dated from 13 January 2020 to 3 March 2021.
No open-market purchase appears, only 3 sales worth €1.9M. Outside the open market, there are 1 option exercise.
The latest filing, published on 3 March 2021, reports an option exercise of €232k in Adaptimmune Therapeutics PLC. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Helen Katrina Tayton-Martin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,785,000 shares@ US$0.15710.9% of flowOrdinary Shares with a nominal value of GBP0.001 per shareSEC:0001104659-21-031733:0
- 200,000 shares@ US$8.7478.6% of flowAmerican Depositary SharesSEC:0001104659-20-090469:0
- 50,000 shares@ US$4.009.5% of flowAmerican Depositary SharesSEC:0001104659-20-004422:0
- 50,000 shares@ US$5.0011.9% of flowAmerican Depositary SharesSEC:0001104659-20-004422:1
4 of 4 declarations
